Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Covid 19 Infection
- COVID-19-Associated Acute Respiratory Distress Syndrome
- Hematopoietic and Lymphoid Cell Neoplasm
- Malignant Solid Neoplasm
- Symptomatic COVID-19 Infection Laboratory-Confirmed
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
PRIMARY OBJECTIVE: I. To assess the safety of administering cord blood derived mesenchymal stem cell (CB-MSC) infusions for treatment of COVID-19 acute respiratory distress syndrome (ARDS). SECONDARY OBJECTIVES: I. In the group of patients who present intubated on ventilator support, assess the prop...
PRIMARY OBJECTIVE: I. To assess the safety of administering cord blood derived mesenchymal stem cell (CB-MSC) infusions for treatment of COVID-19 acute respiratory distress syndrome (ARDS). SECONDARY OBJECTIVES: I. In the group of patients who present intubated on ventilator support, assess the proportion that are able to be successfully extubated. II. In the group of patients who present requiring supplemental oxygen but otherwise breathing without assistance, assess the rate of progression to intubation. III. Estimate the survival rate at day 30 post treatment separately by group. IV. Determine the treatment effect on clinical parameters, oxygenation and respiratory parameters: IVa. Resolution of fever. IVb. Changes in oxygen demand (increased oxygen saturation at similar fraction of inspired oxygen [FiO2] or decreased FiO2 requirement). IVc. Progression to mechanical ventilation. IVd. Length of mechanical ventilation. IVe. Decrease in positive end-expiratory pressure (PEEP) in intubated patients. IVf. Decrease in FiO2 in intubated patients. V. Determine the treatment effect on laboratory markers: Va. Complete blood count. Vb. C-reactive protein (CRP). Vc. Ferritin. Vd. D dimer. Ve. Procalcitonin. Vf. Cytokine levels. VI. Estimate hospitalization and intensive care unit (ICU) stay. VII. Report on study related adverse events. OUTLINE: Currently not shipping cells outside of MD Anderson Cancer Center in Houston. PILOT STUDY: Patients receive MSCs intravenously (IV) over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion. PHASE II STUDY: Patients are randomized to 1 of 2 arms. ARM I: Patients receive MSCs IV over 1-2 hours on day 1. Patients may receive a second infusion of MSCs within 7 days after the first infusion per physician discretion. ARM II: Patients receive standard of care. After completion of study treatment, patients are followed up at days 7, 14, 30, 60, and months 6 and 12.
Tracking Information
- NCT #
- NCT04565665
- Collaborators
- National Cancer Institute (NCI)
- Investigators
- Principal Investigator: Amanda Olson M.D. Anderson Cancer Center